Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT06242834 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Non-Hodgkin Lymphoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography
BIOLOGICAL: Pembrolizumab
PROCEDURE: Positron Emission Tomography
DRUG: Tazemetostat

Sponsor

Northwestern University

Collaborators

[object Object]